Pick our brains session
Q&A with female leaders in Life Sciences
22 September | 16:10-16:45
Pick our brains session
Q&A with female leaders in Life Sciences
22 September | 16:10-16:45
About Eline van Beest | CEO, Hybridize
About Eline van Beest | CEO, Hybridize
Eline founded the MedTech scale-up NightBalance in 2009 with a new therapy for sleep apnea. NightBalance was acquired by Philips in May 2018. Currently, she is the CEO of Hybridize Therapeutics, a spin-off from the LUMC that develops RNA-based therapies for viral infections. Furthermore, she is a Venture Partner at Thuja Capital. Also, she holds a position as a member of the Supervisory Board of Livassured, a company that introduces a smart wearable that warns caretakers on epileptic seizures. Eline was nominated for several lists of female and/or tech entrepreneurs like Quote, Glamour, Viva, Opzij, Financieel Dagblad, Sprout, The Inspiring 50, World Women's Forum and 35 Innovators Under 35 by MIT (2018).
About Hybridize Therapeutics
Hybridize Therapeutics is a spin-off from the Leiden University Medical Center (LUMC). The LUMC has played a pioneering role in both nephrology and RNA-based medicine since 1943 as both the dialysis machine and the first antisense oligonucleotide were invented at this institute. Hybridize combines these areas in its mission, focusing on helping patients overcome untreated kidney diseases with high unmet medical needs using RNA-based therapeutics. Hybridize’s lead program focuses on the BK-virus. In addition, the Company is expanding its pipeline into kidney monogenic diseases and anti-inflammation/fibrosis.
For more information, please visit www.hybridizetherapeutics.com.
Hybridize Therapeutics is a spin-off from the Leiden University Medical Center (LUMC). The LUMC has played a pioneering role in both nephrology and RNA-based medicine since 1943 as both the dialysis machine and the first antisense oligonucleotide were invented at this institute. Hybridize combines these areas in its mission, focusing on helping patients overcome untreated kidney diseases with high unmet medical needs using RNA-based therapeutics. Hybridize’s lead program focuses on the BK-virus. In addition, the Company is expanding its pipeline into kidney monogenic diseases and anti-inflammation/fibrosis.
For more information, please visit www.hybridizetherapeutics.com.
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects